About Us

Who We Are

The Johns Hopkins University Baltimore-Washington-India Clinical Trials Unit (BWI CTU) is a collaboration and integration of 3 separate Clinical Research Sites (CRS’s):
 

The BWI CTU supports clinical studies offered by 4 NIAID Clinical Research Networks

  1. AIDS Clinical Trials Group (ACTG)
  2. HIV Prevention Trials Network (HPTN)
  3. International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
  4. Antibiotic Resistance Leadership Group (ALRG).

The BWI CTU works with patients from two diverse, urban U.S. communities with high burdens of and high risks for HIV and Hepatitis C (Baltimore and Washington, DC), as well as one of the largest HIV/infectious diseases clinical care and clinical research units on the Indian subcontinent.

The BWI CTU includes a highly experienced international leadership that is also uniquely positioned to make significant and strategic scientific contributions. 
 

Three Specific Aims

  1. Science. The BWI CTU’s innovative Scientific Coordinating Committees bring together expertise in our strongest fields: Tuberculosis, Hepatitis, HIV Cure, HIV Prevention, Clinical Pharmacology, Pediatric & Adolescent Research, Inflammation & End-Organ Complications, Antibiotic Resistance, and Training & Mentorship.

    The Committees are highly creative in developing new study proposals, identifying and prioritizing studies for site implementation, and encouraging young and international investigators to contribute to novel scientific concepts valued by the networks we support.

  2. Populations. Our three CRS sites work with very important and often under-represented populations.

    1. Impoverished urban African-Americans and other communities of color, those with a history of intravenous drug use and substance abuse in Baltimore and Washington
    2. Vulnerable sexually active young urban MSM and women in Baltimore and Washington
    3. Pregnant women, adolescents and adults in urban India.


    Because all three sites provide top-quality clinical care and clinical research at the same facility, we can efficiently identify potential research participants and rapidly enroll them into high priority research using our integrated clinical care and clinical research teams.

  3. Management. Our efficient and highly integrated administrative structure facilitates high quality clinical research while taking advantage of shared resources, investigator expertise and synergies among sites.

Clinical Trials

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More